Novel Patch-Based Ebolavirus Diagnostic to Help Quickly Identify and Treat Infected Individuals

The novel, single-use, rapid ebolavirus diagnostic will combine Satio, Inc.’s (Boston, MA, USA) patch-based blood collection device with an ebolavirus immunoassay from Institut Pasteur de Dakar (Dakar, Senegal). Satio is working on a suite of patch-based platforms, including SatioDot optimized for dried blood spots, and SatioDraw designed for comprehensive whole blood collection, which can cater to an extensive array of lab-based tests. These platforms employ a lancet to gather blood from the upper arm, channeling it into the patch. Satio is now accelerating the development of an integrated blood draw and diagnostic platform with the potential to extend its capabilities for identifying other critical blood-borne pathogens, such as HIV and syphilis.

Satio's groundbreaking designs, covered by patent protection, provide patients with access to simple and cost-effective blood collection options. These solutions facilitate blood extraction, reagent mixing, and the identification of an array of pathogens, all achieved through a patch affixed to the arm. In a remarkable extension, Satio's patch technology also holds the potential for the painless administration of drugs and vaccines. Consequently, this innovation holds the promise to mitigate or even eliminate the necessity for needles and medical professional intervention. By doing away with conventional fingerstick blood samples and the associated external blood sample manipulation, Satio's trailblazing innovation reduces exposure to bloodborne pathogens. Simultaneously, it offers an exceptional, budget-friendly diagnostic tool for easy deployment at the point of need, thereby advancing patient outcomes and restricting the spread of ebolavirus.

Related Links:
Satio, Inc.
Institut Pasteur de Dakar